[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354043-105":59,"doc-detail-354043-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genetic-alterations-involved-in-immune-escape-mechanisms-of-circulating-tumour-cells-in-colorectal-carcinogenesis","Genetic Alterations Involved in Immune Escape Mechanisms of Circulating Tumour Cells in Colorectal Carcinogenesis","","Colorectal cancer (CRC) circulating tumour cells use genetic alterations to evade immune surveillance. The study highlights changes in driver genes such as KRAS, BRAF, p53, MYC, APC and PTEN, which shape tumour–immune interactions. These alterations can regulate immune checkpoint expression, including PD-1, PD-L1, PD-L2, CTLA-4 and CD47, thereby dampening antitumour responses and supporting growth. The precise links between driver mutations and checkpoint profiles in CTCs, and their clinical relevance, remain incompletely defined, motivating research toward therapeutic targets and improved liquid biopsy insights.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genetic-alterations-involved-in-immune-escape-mechanisms-of-circulating-tumour-cells-in-colorectal-carcinogenesis/354043/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genetic-alterations-involved-in-immune-escape-mechanisms-of-circulating-tumour-cells-in-colorectal-carcinogenesis/354043.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which driver genes are discussed as key players in CRC immune escape mechanisms of CTCs?","Question",{"text":112,"@type":113},"KRAS, BRAF, p53, MYC, APC and PTEN are identified as driver genes whose genetic alterations can influence tumour–immune interactions in CRC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do the described genetic alterations affect immune checkpoint molecule expression?",{"text":117,"@type":113},"Changes in driver genes are linked to altered expression of immune checkpoint molecules such as PD-1, PD-L1, PD-L2, CTLA-4 and CD47, which can suppress immune responses against tumour cells.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are circulating tumour cells (CTCs) important for CRC monitoring and liquid biopsy?",{"text":121,"@type":113},"CTCs provide a minimally invasive monitoring approach compared with tissue biopsy, and their hereditary profiles support immune surveillance evasion, which can improve the clinical implications of liquid biopsy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354043,1790193672,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer Medicine  \n|  REVIEW  OPEN ACCESS \u003Cbr>Genetic Alterations Involved in Immune Escape Mechanisms of Circulating Tumour Cells in\u003Cbr>Colorectal Carcinogenesis\u003Cbr>Sharmin Aktar1,2,3 | Matthew Masoudi1 | Dilpreet Moti1 | Vinod Gopalan1 | Farhadul Islam1,4  | Alfred King-yin Lam1,5 \u003Cbr>1School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia | 2Rural Health Research Institute, Charles Sturt University, Orange, New South Wales, Australia | 3Department of Biochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh | 4Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh | 5Pathology Queensland, Gold Coast University Hospital, Southport, Queensland, Australia\u003Cbr>Correspondence: Alfred King-yin Lam ([a.lam@griffith.edu.au](a.lam@griffith.edu.au))\u003Cbr>Received: 25 April 2025 | Revised: 3 November 2025 | Accepted: 16 February 2026\u003Cbr>Keywords: circulating tumour cells | colorectal cancer | immune escape | immune surveillance | oncogenes | tumour suppressors |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>In colorectal cancer (CRC), circulating tumour cells (CTCs) employ genetic alterations to dodge the body's immune system. These alterations occur in specific “driver” genes, including KRAS, BRAF, p53, MYC, APC and PTEN. Changes in these genes can control how the tumour interacts with the immune system and influence the expression of immune checkpoint molecules such as PD-1, PD-L1, PD-L2, CTLA-4 and CD47. These molecules help suppress the immune system's response against the tumour, thus promoting tumour growth. However, the precise relationship between driver gene mutations and the expression of immune checkpoint molecules in CTCs, along with their clinical significance, remains incompletely understood. By studying these genetic changes and how they affect the behaviour of CTCs, researchers can gain critical insights into the development and progression of CRC, especially the roles of CTCs, which could improve CTCs' implications in liquid biopsy. Moreover, understanding these alterations can also highlight potential therapeutic targets. This may pave the way for more effective, targeted therapies to delay or prevent CRC progression. Therefore, investigating the genetic alterations in CTCs and their role in immune escape mechanisms is a significant area of study in CRC research. |  |\n| 1 | Introduction | together drive the adenoma–adenocarcinoma sequence of CRC progression [1, 2] . |\n| The carcinogenesis of colorectal carcinoma (CRC) is based on |  |\n| a stepwise aggregation of genetic and epigenetic changes, lead- | Understanding the biology of CRC pathogenesis has driven |\n| ing to either the activation of oncogenes or the deactivation of | noteworthy breakthroughs and has developed novel therapeutic |\n| tumour suppressors. An accumulation of these genetic and/or | targets, which have made strides for the clinical management |\n| epigenetic drift-induced genomic instability drives CRC patho- | of patients with CRC. For instance, the discovery and advance- |\n| genesis. For example, hereditary predisposition triggers the ac- | ment of immune checkpoint inhibitors, such as anti-PD-L1 and |\n| tivation of proto-oncogenes (e.g., KRAS) and the inactivation of | anti-CTLA-4 antibodies, have demonstrated encouraging out- |\n| tumour suppressor qualities, specifically p53 and APC, which | comes, both as standalone therapies and in combination, across |\n| Sharmin Aktar and Matthew Masoudi are co-first authors as they contributed equally to this article. |  |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |  |\n\nCancer Medicine, 2026; 15:e71683 1 of 17  \n[https://doi.org/10.1002/cam4.71683](https://doi.org/10.100","cbCaiuRfN6Qym1b2","https://ap.wps.com/l/cbCaiuRfN6Qym1b2","pdf",2894184,17,"English","# Introduction\n## Genetic and epigenetic basis of colorectal carcinogenesis\n## Driver genes and tumour–immune system crosstalk\n## Immune checkpoint regulation and CRC risk\n## Circulating tumour cells in cancer monitoring\n## Purpose and scope of the review","[{\"question\":\"Which driver genes are discussed as key players in CRC immune escape mechanisms of CTCs?\",\"answer\":\"KRAS, BRAF, p53, MYC, APC and PTEN are identified as driver genes whose genetic alterations can influence tumour–immune interactions in CRC.\"},{\"question\":\"How do the described genetic alterations affect immune checkpoint molecule expression?\",\"answer\":\"Changes in driver genes are linked to altered expression of immune checkpoint molecules such as PD-1, PD-L1, PD-L2, CTLA-4 and CD47, which can suppress immune responses against tumour cells.\"},{\"question\":\"Why are circulating tumour cells (CTCs) important for CRC monitoring and liquid biopsy?\",\"answer\":\"CTCs provide a minimally invasive monitoring approach compared with tissue biopsy, and their hereditary profiles support immune surveillance evasion, which can improve the clinical implications of liquid biopsy.\"}]","Genetic Alterations Involved in Immune Escape Mechanisms of Circulating Tumour Cells in Colorectal Carcinogenesis | PDF",1790108557,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dcc1079dab7f06c8d822b17392c2b17f.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9972878c122292a6baaf3a8414ac6f67.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a3b174bc8f61276990060d03331d57c.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1b4618c03760efbebca38b6d978039b.webp",980,1287]